Volume : 11, Issue : 11, November – 2024
Title:
AWARENESS AND PERCEPTION OF INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE AMONG THE GENERAL POPULATION IN TAIF CITY, SAUDI ARABIA
Authors :
Naif Edah Alomairi
Abstract :
Abstract:
Background: Stroke ranks as the second leading cause of dementia and death globally. Despite the established effectiveness of tissue plasminogen activator (tPA) in treating ischemic stroke, its use remains limited worldwide.
Objectives: This study evaluates the awareness, knowledge, and attitudes of adults regarding stroke symptoms, thrombolytic therapy for acute ischemic stroke (AIS), and the critical treatment window.
Materials and Methods: Conducted in Taif, Saudi Arabia, from March to April 2024, this cross-sectional study involved 272 Saudi adults aged 18-60 years, selected through a convenience sampling method. Data collection was done via a self-administered online questionnaire in Arabic, which included demographic details, personal or family history of AIS, knowledge about stroke, and sources of information.
Results: Participants were mainly aged 36-55 years (43%) and female (67.4%). A personal or family history of AIS was reported by 44.1%. About 52.9% demonstrated sufficient knowledge of stroke and thrombolytic therapy. Family and friends (42.3%) and the internet and social media (40.4%) were the main information sources. Logistic regression indicated that using newspapers/medical magazines and information from family/friends were linked to significantly better knowledge (AOR=0.13, CI: 0.01-0.42, p=0.002 and AOR=0.34, CI: 0.12-0.96, p=0.041, respectively). Having multiple sources of information significantly reduced the risk of insufficient knowledge (AOR=0.06, CI: 0.02-0.19, p<0.001 and AOR=0.15, CI: 0.05-0.49, p=0.002).
Conclusion: The general population in Taif has adequate knowledge of stroke symptoms and thrombolytic therapy, but gaps remain in recognizing some symptoms and the critical time window for tPA administration.
Keywords: Stroke, Thrombolysis, Time window, Knowledge, General population.
Cite This Article:
Please cite this article in press Naif Edah Alomairi ., Awareness And Perception Of Intravenous Thrombolysis For Acute Ischemic Stroke Among The General Population In Taif City, Saudi Arabia..,Indo Am. J. P. Sci, 2024; 11 (11).
Number of Downloads : 10
References:
1. Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020, 21:7609. 10.3390/ijms21207609
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
3. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, et al. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neur2007; 6: 456-464.
4. Wang YL, Wu D, Zhou Y, Zhao XQ, Wang CX, Liu L, et al. Thrombolysis in the Emergency Department in China: Results from an Emergency Department Registry in 7 Urban Hospitals. Chinese Journal of Stroke 2009; 4: 23-28.
5. Deng YZ, Reeves MJ, Jacobs BS, Birbeck GL, Kothari RU, Hickenbottom SL, et al. IV tissue plasminogen activator use in acute stroke experience from a statewide registry. Neurology. 2006 Feb 14;66(3):306-12. doi: 10.1212/01.wnl.0000196478.77152.fc.
6. Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry 2011;82: 14-19. doi: 10.1136/jnnp.2009.203174.
7. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018; 49:e46-e110. 10.1161/STR. 0000000000000158
8. Anderson BE, Rafferty AP, Lyon-Callo S, Fussman C, Reeves MJ. Knowledge of tissue plasminogen activator for acute stroke among Michigan adults. Stroke 2009; 40: 2564–2567.
9. Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke. 2013; 8:681-8. 10.1111/j.1747-4949.2012.00844.x
10. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011; 42:1952-5. 10.1161/STROKEAHA.110.612358
11. Yang J, Zheng M, Chen S, Ou S, Zhang J, Wang N, et al. Knowledge of thrombolytic therapy for acute ischemic stroke among community residents in Western Urban China. PLoS ONE 2014; 9(9): e107892. doi:10.1371/journal.pone.0107892
12. Ahmed HJ, Yassin R, Yassin D, Elkhidir I. Knowledge and attitude of Sudanese emergency registrars towards the use of tissue plasminogen activator in the management of acute ischemic stroke. Cureus 2022 Oct; 14(10): e29908. DOI 10.7759/cureus.29908
13. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014, 384:1929-35. 10.1016/S0140-6736(14)60584-5
14. Al Khathaami AM, Aloraini H, Almudlej S, Al Issa H, Elshammaa N, Alsolamy S. Knowledge and attitudes of Saudi emergency physicians toward t-PA use in stroke. Neurology Research International. 2018; Volume 2018, 3050278, 7 pages. https://doi.org/10.1155/2018/3050278
15. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011; 42:1658-64. 10.1161/STROKEAHA. 110.604249
16. World population Review. Taif population 2024. Available at: https://worldpopulationreview.com/world-cities/taif-population.
17. Bartlett J. Kotrlik JW, Higgins CC. Organizational Research: Determining Appropriate Sample Size in Survey Research, 2001. Retrieved January 15, 2018,from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1. 486.8295&rep=rep1&type=pdf.
18. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. N Engl J Med 2024;390 (8):701-71. DOI: 10.1056/NEJMoa2310392